MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Progression of neuropsychiatric symptoms in Parkinson’s disease

J. Dlay, G. Duncan, T. Khoo, C. Williams-Gray, D. Breen, R. Barker, D. Burn, R. Lawson, A. Yarnall (Newcastle Upon Tyne, United Kingdom)

Meeting: 2019 International Congress

Abstract Number: 366

Keywords: Neurobehavioral disorders, Parkinsonism

Session Information

Date: Monday, September 23, 2019

Session Title: Psychiatric Manifestations

Session Time: 1:45pm-3:15pm

Location: Les Muses Terrace, Level 3

Objective: To determine the progression of neuropsychiatric symptoms (NPS) in Parkinson’s disease (PD) and their associations with quality of life (QoL) and motor problems.

Background: Emerging evidence suggests non-motor symptoms including NPS may predate the onset of motor problems. NPS occur in over 60% of PD patients, leading to increased risk of institutionalisation. At present there are few longitudinal studies assessing the burden of NPS on QoL in non-demented PD patients and caregivers.

Method: Patients with newly diagnosed idiopathic PD (n=212) and controls (n=99) were recruited to the Incidence of Cognitive Impairment in Cohorts with Longitudinal Evaluation-PD (ICICLE-PD) study. Participants completed the Neuropsychiatric Inventory with Caregiver Distress scale (NPI-D) to measure NPS; Parkinson’s Disease Questionnaire (PDQ‐39) to measure QoL; Movement Disorders Society Unified Parkinson’s Disease Rating Scale Part III (MDS-UPDRS III) to measure severity of motor impairments; and Montreal Cognitive Assessment (MoCA) to measure global cognition. Assessments were repeated at 18 and 36-month follow-up. Multivariate linear regression was used to predict NPI-D and QoL, adjusting for confounding variables.

Results: Hallucinations, depression, anxiety and apathy were more common in PD subjects than controls at each time point (p<0.05 for all). Irritability, sleep disturbances and appetite changes were significantly higher in PD subjects than controls at 18 months, with appetite changes still significant at 36 months (p<0.05). Lower MoCA and higher MDS-UPDRS-III scores at 36 months were significant predictors of NPI total score at this time point (β=-0.260, p=0.010; β=0.411, p<0.001 respectively) but not at baseline (p>0.05). Higher NPI-D score was a significant determinant of poorer QoL at both baseline (ΔR2=0.063, p<0.05) and this was consistent at 36 months (ΔR2=0.041, p<0.05).

Conclusion: Prevalence of NPS is higher in PD compared to controls and is associated with greater motor problems and poorer QoL. Clinicians should be aware of their frequency, since earlier identification of patients with NPS at diagnosis will allow provision of specialist support.

To cite this abstract in AMA style:

J. Dlay, G. Duncan, T. Khoo, C. Williams-Gray, D. Breen, R. Barker, D. Burn, R. Lawson, A. Yarnall. Progression of neuropsychiatric symptoms in Parkinson’s disease [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/progression-of-neuropsychiatric-symptoms-in-parkinsons-disease/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/progression-of-neuropsychiatric-symptoms-in-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley